Baxdrostat is a small molecule commercialized by AstraZeneca, with a leading Phase III program in Resistant Hypertension. According to Globaldata, it is involved in 25 clinical trials, of which 15 were completed, 7 are ongoing, and 3 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Baxdrostat’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Baxdrostat is expected to reach an annual total of $89 mn by 2035 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Baxdrostat Overview
Baxdrostat is under development for the treatment of chronic kidney disease (CKD), resistant hypertension, idiopathic essential hypertension and primary hyperaldosteronism. The drug candidate acts by targeting aldosterone synthase (CYP11B2). It is administered through oral and intravenous route. It was under development for the treatment of congenital vascular malformation and atherosclerosis.
AstraZeneca Overview
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
The company reported revenues of (US Dollars) US$45,811 million for the fiscal year ended December 2023 (FY2023), an increase of 3.3% over FY2022. In FY2023, the company’s operating margin was 17.9%, compared to an operating margin of 8.5% in FY2022. In FY2023, the company recorded a net margin of 13%, compared to a net margin of 7.4% in FY2022.
The company reported revenues of US$12,938 million for the second quarter ended June 2024, an increase of 2% over the previous quarter.
For a complete picture of Baxdrostat’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.